Tech Center 1600 • Art Units: 1636
This examiner grants 80% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18042729 | VIRAL VECTOR ENCODING GLP-1 RECEPTOR AGONIST FUSIONS AND USES THEREOF IN TREATING METABOLIC DISEASES IN FELINES | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18023259 | GENE KNOCK-OUT FOR TREATMENT OF GLAUCOMA | Final Rejection | University of Iowa Research Foundation |
| 17602540 | PIP4Ks SUPPRESS INSULIN SIGNALING AND ENHANCE IMMUNE FUNCTION THROUGH A CATALYTIC-INDEPENDENT MECHANISM | Non-Final OA | Cornell University |
| 18066890 | GENETIC FACTOR TO INCREASE EXPRESSION OF RECOMBINANT PROTEINS | Non-Final OA | Impossible Foods Inc. |
| 17104372 | TARGETED GENE ACTIVATION USING MODIFIED GUIDE RNA | Final Rejection | Salk Institute for Biological Studies |
| 18096538 | miRNA, and Derivative Thereof and Use Thereof | Non-Final OA | South China Normal University |
| 17633593 | Antisense oligonucleotides rescue aberrant splicing of ABCA4 | Non-Final OA | UCL Business Ltd |
| 18000640 | PROGRAMMABLE NUCLEASES AND METHODS OF USE | Non-Final OA | Mammoth Biosciences, Inc. |
| 18269582 | Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of KRT5, KRT14, LAMB3, and COL7A1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-KRT5, or Escherichia coli strain SCS110-AF/VTvaf17-KRT14, or Escherichia coli strain SCS110-AF/VTvaf17-LAMB3, or Escherichia coli strain SCS110-AF/VTvaf17-COL7A1 carrying the gene therapy DNA vector, m | Non-Final OA | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU "PRORYVNYE INNOVATSIONNYE TEKHNOLOGII" |
| 17612547 | TREATMENT OF ALT CANCERS | Non-Final OA | TESSELLATE BIO BV |
| 18049903 | TDP-43 MODULATING AGENTS AND USES THEREOF | Non-Final OA | UNITED STATES GOVERNMENT |
| 17923659 | METHOD OF MODIFYING A YEAST STRAIN, MODIFIED YEAST STRAINS OBTAINED THEREBY AND USES THEREOF | Non-Final OA | STELLENBOSCH UNIVERSITY |
| 17775626 | USE OF CAS9 PROTEIN FROM THE BACTERIUM PASTEURELLA PNEUMOTROPICA | Final Rejection | JOINT STOCK COMPANY "BIOCAD" |
| 17811414 | TUNABLE TRANSPOSON SYSTEMS | Non-Final OA | Aridis Pharmaceuticals, Inc. |
| 17615427 | USES OF TREM COMPOSITIONS TO MODULATE TRNA POOLS | Final Rejection | FLAGSHIP PIONEERING, INC. |
| 17423700 | TREM COMPOSITIONS AND USES THEREOF | Non-Final OA | FLAGSHIP PIONEERING, INC. |
| 17995223 | GENOME EDITING METHOD BASED ON CRISPR/CAS9 SYSTEM AND USE THEREOF | Final Rejection | CHUNGANG UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION |
| 17627853 | Methods to determine the effect of an agent on mammalian embryonic development | Final Rejection | Toxys B.V. |
| 17625433 | FUNCTIONAL NUCLEIC ACID MOLECULES UPREGULATING THE TRANSLATION OF A FRATAXIN MRNA | Non-Final OA | Scuola Internazionale Superiore Studi Internazionale Superiore Di Studi Avanzati - SISSA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy